No Data
No Data
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
Leerink Partners Maintains Structure Therapeutics(GPCR.US) With Buy Rating
Buy Rating Backed by Strategic Partnership Opportunities and Strong Patent Portfolio for Structure Therapeutics
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Rivals Emerge to Ozempic and Zepbound -- but With a Lag -- Heard on the Street -- WSJ
Express News | Shares of Weight Loss Stocks Are Trading Lower, Possibly on Continued Weakness Following Recent Weight Loss Data From Roche, Which Could Cause Competition Concerns for Companies in the Space
No Data